2017
1. Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA.
Schrom E, Huber M, Aneja M, Dohmen C, Emrich D, Geiger J, Hasenpusch G, Herrmann-Janson A, Kretzschmann V, Mykhailyk O, Pasewald T, Oak P, Hilgendorff A, Wohlleber D, Hoymann HG, Schaudien D, Plank C, Rudolph C, Kubisch-Dohmen R
Mol Ther Nucleic Acids. 2017 Jun 16.
2015
2. Nanomagnetic activation as a way to control the efficacy of nucleic Acid delivery.
Grześkowiak BF, Sánchez-Antequera Y, Hammerschmid E, Döblinger M, Eberbeck D, Woźniak A, Słomski R, Plank C, Mykhaylyk O
Pharm Res. 2015 Jan .
3. Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro.
Mykhaylyk O, Sanchez-Antequera Y, Vlaskou D, Cerda MB, Bokharaei M, Hammerschmid E, Anton M, Plank C
Methods Mol Biol. 2015 .
8. Optimizing adenoviral transduction of endothelial cells under flow conditions.
Anton M, Wolf A, Mykhaylyk O, Koch C, Gansbacher B, Plank C
Pharm Res. 2012 May .
9. Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria.
Mykhaylyk O, Sobisch T, Almstätter I, Sanchez-Antequera Y, Brandt S, Anton M, Döblinger M, Eberbeck D, Settles M, Braren R, Lerche D, Plank C
Pharm Res. 2012 May .
10. Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles.
Mannell H, Pircher J, Fochler F, Stampnik Y, Räthel T, Gleich B, Plank C, Mykhaylyk O, Dahmani C, Wörnle M, Ribeiro A, Pohl U, Krötz F
Nanomedicine. 2012 Nov .
